The Dermatology Digest

FEBRUARY 18, 2025

Food and Drug Administration (FDA) approved mirdametinib (Gomekli, SpringWorks) for the treatment of adult and pediatric patients aged two and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection. Gomekli is an oral, small molecule MEK inhibitor.

Networking 64

Networking Safety Innovations Management 64

The Dermatology Digest

MARCH 18, 2025

has completed enrollment in its Phase 3 clinical trial evaluating aminolevulinic acid hydrochloride (Ameluz) with photodynamic therapy (PDT) for the treatment of mild to moderate actinic keratoses (AKs) on the extremities, neck, and trunk. They are then followed up for approximately one year after the last PDT treatment.

Treatments 36

Treatments Dermatology Safety Therapy 36

The Dermatology Digest

MARCH 3, 2025

” A double-blinded, randomized, placebo-controlled trial evaluated the safety and efficacy of BioRewind in 104 patients over 12-weeks. ”: The post This Week’s Hottest Drops, Launches, and Collabs appeared first on The Dermatology Digest. We are confident this innovation will redefine how we think about skin health.”

Medical Grade Skincare 74

Medical Grade Skincare Social Media Branding Skin Health 74

US Dermatologt Partners

JANUARY 13, 2025

Dermatology Partners Fairfax , Whether patients are dealing with persistent blackheads, painful cystic acne, or stubborn whiteheads, the temptation to pop or pick at acne is hard to resist. Acne extractions also make it possible for acne treatments to be more effective because they are able to penetrate into pores more easily.

Extractions 41

Extractions Scarring Pores Chemical Peels 41

Dermatology Times

JUNE 10, 2024

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

Safety 73

Safety Treatments Dermatitis 73

Dermatology Times

APRIL 12, 2024

She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment. Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives.

Dermatitis 85

Dermatitis Treatments Safety Management 85

The Dermatology Digest

JANUARY 8, 2025

Medical spas in Las Vegas, NV, lack on-site physician supervision, according to a study by the the American Society for Dermatologic Surgery Association (ASDSA). Of the 63 medical spas reviewed, 73% of treatments involving injections were performed by non-physicians. Laurin Council, MD, MBA, ASDS/A President, in a news release.

Medical 36

Medical Social Media Safety Training 36

The Dermatology Digest

JULY 24, 2024

Stelara is a currently approved treatment for adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn’s, and moderately to severely active ulcerative colitis.

Dermatology 78

Dermatology Sales Marketing Safety 78

The Dermatology Digest

MARCH 5, 2025

first pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial of Xyngari, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The XYNGARI Phase 3 STAR-1 clinical study will evaluate the efficacy, safety, and tolerability of Xyngari in patients with moderate-to-severe facial acne.

Treatments 36

Treatments Rosacea Pores Office 36

Lipgloss and Aftershave

NOVEMBER 1, 2024

Jenni Nagle, L+A CO-Founder had a CO2 laser treatment and kept an eight day diary of her recovery process! For estheticians and skincare professionals, addressing pigmentation involves understanding and applying a multimodality treatment approach, which combines various techniques to tackle pigmentation through multiple mechanisms.

Chemical Peels 52

Chemical Peels Vitamin C Hyperpigmentation Microneedling 52

The Dermatology Digest

DECEMBER 11, 2024

Despite disappointing efficacy, ANB032 was well tolerated with no safety signals observed, the Company reported. The ARISE-AD study evaluated the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ANB032 monotherapy in patients with moderate-to-severe AD.

Safety 36

Safety Dermatitis Therapy Dermatology 36

The Dermatology Digest

APRIL 7, 2024

A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Nonsteroidal treatment options for AD have rapidly expanded in recent years with the development of phosphodiesterase-4 inhibitors, biologics, and Janus kinase (JAK) inhibitors.

Treatments 77

Treatments Dermatitis Therapy Medical 77

The Dermatology Digest

MARCH 8, 2025

The research was presented as a late-breaker at the 2025American Academy of Dermatology(AAD) Annual Meeting inOrlando, FL. The Phase 3 TRuE-PN clinical trial program comprises TRuE-PN1 and TRuE-PN2 studies, which evaluate the safety and efficacy of twice-daily ruxolitinib cream 1.5% The overall safety profile of ruxolitinib cream 1.5%

Safety 36

Safety Clinic Therapy Dermatology 36

Dermatology Times

JANUARY 9, 2024

Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.

Safety 77

Safety Education Therapy Management 77

The Dermatology Digest

FEBRUARY 17, 2025

Considering risks vs. benefits of cosmetic treatments While four in 10 parents, and more mothers than fathers, say they know someone who has had a non-surgical cosmetic procedure, just 7% of parents of teen girls compared to 1% of parents of teen boys say their teen has asked about getting one.

Social Media 57

Social Media Hair Removal Safety Surgery 57

The Dermatology Digest

NOVEMBER 30, 2024

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

Dermatology Times

NOVEMBER 5, 2024

As news of benzene contamination in benzoyl peroxide products continues to raise safety discussions, Steve Xu, MD, MSc, advocates for stricter regulations, increased research, and the consideration of safer acne treatment alternatives.

Treatments 73

Treatments Safety 73

The Dermatology Digest

MARCH 10, 2025

improves moderate-to-severe nail psoriasis, according to new research presented at the 2025American Academy of Dermatology(AAD) Annual Meeting in Orlando, FL. ” The post Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO appeared first on The Dermatology Digest.

Pharmaceutical 36

Pharmaceutical Safety Clinic Injections 36

The Dermatology Digest

MARCH 17, 2025

The multi-center, randomized, double-blind, placebo-controlled, proof-of-concept trial is designed to evaluate the safety and efficacy of EVO301 in approximately 60 adult patients with moderate-to-severe AD. “AD is a highly heterogenous disease, and for this reason, there remains a need for more effective treatments.

Dermatitis 36

Dermatitis Eczema Injections Tools 36

The Dermatology Digest

JANUARY 10, 2025

Specifically, CGB-500 had an 8-week treatment success of 95% (Investigator’s Global Assessment or IGA core of “0” or “1” and > 2 grade improvement ). This larger Phase 2b trial (n=180) will focus on optimizing dosing regimens and further assessing the safety and efficacy of CGB-500.

Dermatitis 36

Dermatitis Safety Technology Dermatology 36

The Dermatology Digest

MARCH 17, 2025

The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated. “The positive Phase 3 data highlights the potential of povorcitinib as an effective oral treatment option for people living with HS. .

Safety 36

Safety Document Clinic Therapy 36

The Dermatology Digest

JANUARY 8, 2025

topical ET-02 may be more effective than existing treatments for androgenic alopecia, according to results of a first-in-man clinical trial. A final assessment of the subjects was made one week after the treatments ended. Key results of the study showed: Safety: ET-02 was found to be safe and well tolerated.

Safety 36

Safety Clinic Pharmaceutical Treatments 36

The Dermatology Digest

APRIL 12, 2024

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69

Safety Surgery Medical Training 69

The Dermatology Digest

FEBRUARY 25, 2025

This announcement follows the successful completion of a Phase I clinical trial involving 40 healthy volunteers, where ruxoprubart demonstrated promising results and a clean safety profile, with no serious adverse events reported. FDA Approves IND for Ruxoprubart in DM appeared first on The Dermatology Digest. The post U.S.

Safety 36

Safety Therapy Clinic Dermatology 36

Dermatology Times

MAY 13, 2024

5 experts share insights on long-term safety, efficacy, demographic variances, and more in pediatric AD.

Safety 74

Safety Treatments 74

The Dermatology Digest

DECEMBER 3, 2024

The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization in Great Britain for delgocitinib cream (Anzupgo, Leo Pharma) for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate.

Marketing 36

Marketing Eczema Safety Management 36

The Dermatology Digest

NOVEMBER 18, 2024

Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. of participants experiencing a treatment emergent adverse event (TEAE) at week 16. ” The post PsO Pipeline Update: Icotrokinra, an Oral IL-23 Blocker, Looks Good in Topline Phase 3 Data appeared first on The Dermatology Digest.

Safety 36

Safety Medical Innovations Dermatology 36

The Dermatology Digest

JANUARY 22, 2025

for review for the topical treatment of scalp and body psoriasis in patients aged 12 and up. Safety and Tolerability:Roflumilast foam was well tolerated across studies, with treatment-emergent adverse events (TEAEs) predominantly mild to moderate in severity. for the treatment of seborrheic dermatitis in patients 9 and older.

Dermatitis 36

Dermatitis Safety Treatments Dermatology 36

Southeastern Esthetics Institute

AUGUST 23, 2016

Having a thorough understanding of the dermatology and plastic surgery procedures, in addition to all new and modern cosmetic procedures on the market, is critical in assisting your clients in answering questions. Having daily and weekly communication when dealing with patients receiving treatment is critical.

Esthetician 195

Esthetician Esthetics Document Office 195

Texas Dermatology

JANUARY 26, 2025

At Texas Dermatology, we offer Botox and Dysport as two of the most popular non-surgical solutions for smoothing fine lines and wrinkles, helping you achieve a refreshed, youthful appearance. Both treatments are FDA-approved and trusted for their safety, effectiveness, and natural-looking results.

Wrinkles 36

Wrinkles Injections Med Spa Safety 36

Dermatology Times

DECEMBER 18, 2024

The new research identified notable improvements in disease severity, sweat reduction, and quality of life for patients treated with sofpironium.

Safety 64

Safety Treatments 64

The Dermatology Digest

JULY 1, 2024

PYZCHIVA has been approved for the treatment of moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis.

Portfolios 74

Portfolios Safety Clinic Injections 74

The Dermatology Digest

JANUARY 29, 2025

Delgocitinib cream 20mg/g bested oral alitretinoin for the treatment of chronic hand eczema, according to the Phase 3 DELTA FORCE trial. The topical pan-Janus kinase (JAK) inhibitor demonstrated superior treatment effects, quality of life improvements, and a more favorable safety profile compared to oral alitretinoin over 24 weeks.

Eczema 36

Eczema Safety Dermatology Therapy 36

The Dermatology Digest

FEBRUARY 20, 2025

VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immune-mediated diseases. Following the 12-week treatment period, all subjects will be followed for a 4-week safety period.

Safety 36

Safety Office Dermatology Treatments 36

The Dermatology Digest

MARCH 3, 2025

Vyjuvek (beremagene geperpavec-svdt, or B-VEC) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. The CHMPs positive opinion includes support for administration of B-VEC in either a health care setting (e.g.,

Therapy 36

Therapy Clinic Hospital Dermatology 36

Dermatology Times

SEPTEMBER 12, 2023

Researchers compared the efficacy of the 2 modalities and found that they were equal in safety, efficacy, and tolerability.

Safety 83

Safety Treatments 83

Texas Dermatology

DECEMBER 24, 2024

To help you maximize your results, Texas Dermatology is sharing the top 3 tips for effective laser hair removal aftercare. This non-invasive treatment uses advanced laser technology to target hair follicles, reducing regrowth and delivering lasting results. What Is Laser Hair Removal?

Hair Removal 36

Hair Removal Waxing Moisturization Med Spa 36